You are here: Industry Insights > TYME

News List

Tyme’s Oncology Research Identifies Potential New Oral Therapy TYME-19 for COVID-19 americanpharmaceuticalreview
August 28, 2020
Tyme Technologies announced a potential new approach to treating COVID-19 using a metabolic agent, TYME-19.
TYME Announces First Patient Dosed in Metastatic Pancreatic Cancer Treatment Trial americanpharmaceuticalreview
January 13, 2020
Tyme Technologies announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval of SM-88 (racemetyrosine) for the third-line treatment of patients with metastatic pancreatic cancer.
Tyme and Eagle Pharmaceuticals partner for cancer candidate oral pharmaceutical-technology
January 09, 2020
Tyme Technologies has entered a strategic collaboration with Eagle Pharmaceuticals for cancer metabolism-based therapy (CMBT) candidate oral SM-88.
TYME Technologies, NYU Langone to Advance Metastatic Cancer Treatment contractpharma
July 31, 2019
Aims to examine TYME’s metabolism-based cancer treatment, SM-88.